Patient-reported outcomes from a phase 3 study of #baricitinib versus placebo or adalimumab in #rheumatoid arthritis: secondary analyses from the RA-BEAM study

http://ard.bmj.com/node/236598.full

To assess the effect of baricitinib on patient-reported outcomes (PROs) in patients with active rheumatoid arthritis and an inadequate response to methotrexate (MTX)

Compared with placebo and adalimumab, baricitinib showed statistically significant improvements (p≤0.05) in HAQ-DI, PtGA, pain, FACIT-F, SF-36 physical component score, EQ-5D index scores and WPAI-RA daily activity at week 12. Improvements were maintained for measures assessed to week 52. Statistically significant improvement in patient diary measures (MJS duration and severity), worst tiredness and worst joint pain were observed for baricitinib versus placebo and adalimumab at week 12 (p≤0.05).

Conclusions Baricitinib provided significantly greater improvement in most PROs compared with placebo and adalimumab, including physical function MJS, pain, fatigue and quality of life. Improvement was maintained to the end of the study (week 52)

#Baricitinib plus #Remdesivir for Hospitalized Adults with #Covid-19
https://2medical.news/2021/01/05/baricitinib-plus-remdesivir-for-hospitalized-adults-with-covid-19/

Severe coronavirus disease 2019 (Covid-19) is associated with dysregulated inflammation. The effects of combination treatment with baricitinib, a Janus kinase inhibitor, plus remdesivir are not known. METHODS We conducted a double-blind, randomized, placebo-controlled trial evaluating baricitinib plus remdesivir in hospitalized adults with Covid-19. All the patients received remdesivir (≤10 days) and either baricitinib (≤14 days) or placebo (control). The primary outcome was the time to …

#Baricitinib reduces 30-day mortality in older adults with moderate-to-severe #COVID-19 pneumonia

https://2medical.news/2021/07/16/baricitinib-reduces-30-day-mortality-in-older-adults-with-moderate-to-severe-covid-19-pneumonia/